ProMIS Neurosciences Inc
TSX:PMN
ProMIS Neurosciences Inc
Cash from Operating Activities
ProMIS Neurosciences Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ProMIS Neurosciences Inc
TSX:PMN
|
Cash from Operating Activities
-$16.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-23%
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Operating Activities
-$118.3m
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Operating Activities
-$127.2m
|
CAGR 3-Years
-176%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Operating Activities
-$81.8m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
-$33.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-22%
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$10.7m
|
CAGR 3-Years
-222%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-2%
|
See Also
What is ProMIS Neurosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-16.5m
USD
Based on the financial report for Mar 31, 2023, ProMIS Neurosciences Inc's Cash from Operating Activities amounts to -16.5m USD.
What is ProMIS Neurosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-23%
Over the last year, the Cash from Operating Activities growth was -44%. The average annual Cash from Operating Activities growth rates for ProMIS Neurosciences Inc have been -48% over the past three years , -22% over the past five years , and -23% over the past ten years .